ERISNSEEris Lifesciences LimitedHighNeutral
Announced Tue, 31 Mar · 18:24 IST

Eris Lifesciences Limited has informed the Exchange regarding 'closure of the transaction related to acquisition of Probiotics business of Velbiom Probiotics Private Limited'.

Listed Co AcquisitionStrategic Transactions View source PDF

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.8%1-day move
₹1296.00
prior close
₹1312.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0+0.4+1.1+0.3+2.8+1.8+1.5+4.5+5.2+7.3+5.6+4.7+6.5+11.8
Up moveDown movePending
AI summary

Eris Lifesciences has completed the acquisition of the Probiotics business of Velbiom Probiotics Private Limited. This is an update to the company's earlier intimation dated March 20, 2026, confirming that the transaction has now achieved closure. The company has informed both BSE and NSE about the completion. No financial details, deal value, or revenue contribution of the acquired business have been disclosed in this update.

Likely market impact

The acquisition is now officially complete, which means the Probiotics business is now part of Eris Lifesciences' portfolio. Shareholders should expect any future revenue or margin contribution from this business to start reflecting in the company's financials, though the size and terms of the deal were not detailed in this closure notice.